What does this research mean for the field?

Fruquintinib demonstrates feasible effectiveness and manageable toxicity in real-world Japanese patients with metastatic colorectal cancer, with proteinuria being the primary cause of early dose modification. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the real-world effectiveness, safety, and factors associated with early dose modification of fruquintinib in routine clinical practice for metastatic colorectal cancer.

August 29, 2026International Journal of Clinical OncologyOpen Access

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study

View Full Paper

Ask AI

Bookmark

Authors

SUShohei UdagawaThe Cancer Institute Hospital CIChihiro IshizukaHokkaido University HOHiroki OsumiKanagawa Prefectural Hospital Organization

Discussion

Member takes

Implication

Retrospective observational study reveals proteinuria drives early fruquintinib dose reductions in metastatic colorectal cancer, indicating the need for close renal monitoring.

Key Points

To evaluate the real-world effectiveness, safety, and factors associated with early dose modification of fruquintinib in routine clinical practice for metastatic colorectal cancer.
Retrospective observational study of N=92 patients with metastatic colorectal cancer treated with fruquintinib across two Japanese cancer centers between November 2024 and December 2025.
Assessed disease control rate, time to treatment failure, overall survival, and adverse events across different starting doses and relative dose intensities with a median follow-up of 5.48 months.
The disease control rate was 37.4% with an objective response rate of 0%; median time to treatment failure was 2.57 months (95% CI, 2.23–3.33) and median overall survival was 8.83 months (95% CI, 7.46–not estimable).
Grade ≥ 3 adverse events occurred in 42.4% of patients and treatment discontinuation occurred in 4.3%, with proteinuria serving as the primary driver of early dose reductions within 28 days (39.1%).

Cite This Study

Udagawa et al. (2026) studied this question.

synapsesocial.com/papers/6a92995f8e5d7d1fc0c113ad https://doi.org/10.1007/s10147-026-03181-1

View Full Paper

Ask AI

Bookmark

August 29, 2026International Journal of Clinical OncologyOpen Access

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study

View Full Paper

Ask AI

Bookmark

Authors

SUShohei UdagawaThe Cancer Institute Hospital CIChihiro IshizukaHokkaido University HOHiroki OsumiKanagawa Prefectural Hospital Organization

Discussion

Member takes

Implication

Retrospective observational study reveals proteinuria drives early fruquintinib dose reductions in metastatic colorectal cancer, indicating the need for close renal monitoring.

Key Points

To evaluate the real-world effectiveness, safety, and factors associated with early dose modification of fruquintinib in routine clinical practice for metastatic colorectal cancer.
Retrospective observational study of N=92 patients with metastatic colorectal cancer treated with fruquintinib across two Japanese cancer centers between November 2024 and December 2025.
Assessed disease control rate, time to treatment failure, overall survival, and adverse events across different starting doses and relative dose intensities with a median follow-up of 5.48 months.
The disease control rate was 37.4% with an objective response rate of 0%; median time to treatment failure was 2.57 months (95% CI, 2.23–3.33) and median overall survival was 8.83 months (95% CI, 7.46–not estimable).
Grade ≥ 3 adverse events occurred in 42.4% of patients and treatment discontinuation occurred in 4.3%, with proteinuria serving as the primary driver of early dose reductions within 28 days (39.1%).

Cite This Study

Udagawa et al. (2026) studied this question.

synapsesocial.com/papers/6a92995f8e5d7d1fc0c113ad https://doi.org/10.1007/s10147-026-03181-1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark